Butantan Institute

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.

Phase 3

Not yet recruiting

Conditions: Dengue
Chikungunya

Interventions: Biological: Chikungunya (CHIKV) live attenuated vaccine (VLA1555)

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Butantan Institute

Target Recruit Count: 900

Registration Number: NCT06973772

Locations: 🇧🇷
Centro Médico de São Francisco, Curitiba, PR, Brazil
🇧🇷
Centro de Pesquisa Inova, Toledo, PR, Brazil
🇧🇷
Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil

and more 4 locations

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

Phase 3

Not yet recruiting

Conditions: Dengue

Interventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine

First Posted Date: 2025-03-24

Last Posted Date: 2025-05-18

Lead Sponsor: Butantan Institute

Target Recruit Count: 997

Registration Number: NCT06891950

Locations: 🇧🇷
Centro de Pesquisa 1 (POA01): Hospital São Lucas - PUCRS, Porto Alegre, Rio Grande do Sul, Brazil

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Phase 1

Not yet recruiting

Conditions: Avian Influenza A Virus

Interventions: Biological: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg
Biological: Monovalent influenza vaccine type A (H5N8) 15 mcg
Other: Placebo

First Posted Date: 2025-02-24

Last Posted Date: 2025-05-18

Lead Sponsor: Butantan Institute

Target Recruit Count: 700

Registration Number: NCT06842173

Locations: 🇧🇷
Centro de Terapias Avançadas E Inovadoras - Ct Terapias/Ufmg, Belo Horizonte, Minas Gerais, Brazil
🇧🇷
Plátano Centro de Pesquisa Clínica LTDA, Recife, Pernambuco, Brazil
🇧🇷
Fundação de Apoio ao Ensino, Pesquisa e Assistência do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preta da Universidade de São Paulo - (Centro de Pesquisa Clínica - S), Serrana, São Paulo, Brazil

and more 2 locations

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Phase 3

Active, not recruiting

Conditions: Influenza, Human

Interventions: Biological: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage
Biological: Quadrivalent Influenza Vaccine (split virion, inactivated)
Biological: Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage

First Posted Date: 2023-03-22

Last Posted Date: 2025-01-31

Lead Sponsor: Butantan Institute

Target Recruit Count: 1373

Registration Number: NCT05779020

Locations: 🇧🇷
Instituto Auto Imune de Pesquisa e Educação Continuada - Real Hospital Português de Beneficência em Pernambuco (Site REC01), Recife, Pernambuco, Brazil
🇧🇷
Centro Oncológico de Roraima - CECOR (Site BVB-01), Boa Vista, Roraima, Brazil
🇧🇷
Centro de Pesquisas Clínicas da Universidade Federal de Sergipe (Site AJU01), Laranjeiras, Sergipe, Brazil

and more 7 locations

Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)

Phase 2

Completed

Conditions: Dengue

Interventions: Biological: Butantan-DV
Biological: V181

First Posted Date: 2023-02-02

Last Posted Date: 2025-01-16

Lead Sponsor: Butantan Institute

Target Recruit Count: 1364

Registration Number: NCT05710224

Locations: 🇧🇷
Hospital São Vicente de Paulo-Education and Research Management (Site 0007), Passo Fundo, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Escola da Universidade Federal de Pelotas (Site 0009), Pelotas, Rio Grande Do Sul, Brazil
🇧🇷
Hospital Tacchini (Site 0006), Bento Gonçalves, Rio Grande Do Sul, Brazil

and more 11 locations

Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine

Phase 2

Completed

Conditions: Healthy
Coronavirus Infections

Interventions: Biological: NDV-HXP-S 10μg
Biological: BNT162b2 30μg

First Posted Date: 2022-04-29

Last Posted Date: 2025-02-06

Lead Sponsor: Butantan Institute

Target Recruit Count: 4400

Registration Number: NCT05354024

Locations: 🇧🇷
Centro de Pesquisa Clínica S, Serrana, São Paulo, Brazil
🇧🇷
Instituto Brasil de Pesquisa Clínica (IBPClin), Rio de Janeiro, Brazil
🇧🇷
Universidade Municipal de São Caetano do Sul, São Caetano Do Sul, São Paulo, Brazil

and more 3 locations

Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil

Phase 1

Completed

Conditions: Healthy
Coronavirus Infections

Interventions: Biological: NDV-HXP-S 3μg
Biological: NDV-HXP-S 1μg
Biological: NDV-HXP-S 10μg
Other: Adsorbed inactivated COVID-19 vaccine (CoronaVac)

First Posted Date: 2021-08-06

Last Posted Date: 2023-08-21

Lead Sponsor: Butantan Institute

Target Recruit Count: 320

Registration Number: NCT04993209

Locations: 🇧🇷
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil

Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine

Completed

Conditions: SARS-CoV-2 Acute Respiratory Disease

Interventions: Biological: Adsorbed COVID-19 (Inactivated) Vaccine

First Posted Date: 2021-04-14

Last Posted Date: 2023-05-22

Lead Sponsor: Butantan Institute

Target Recruit Count: 2549

Registration Number: NCT04845048

Locations: 🇧🇷
Centro de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-USP) Dr. Joel Domingos Machado., Ribeirão Preto, São Paulo, Brazil
🇧🇷
Centro de Saúde Escola da Faculdade de Medicina de Botucatu - Unesp., Botucatu, São Paulo, Brazil
🇧🇷
Centro de Referência de Imunobiológicos Especiais. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (CRIEHCFMUSP), São Paulo, Brazil

Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases

Phase 1

Conditions: Diabetes Mellitus
Cardiovascular Diseases
Immunosuppression
Cancer
Other Complication of Kidney Transplant
Chemotherapy
Renal Disease
Chronic Obstructive Pulmonary Disease
COVID-19

Interventions: Biological: AntiSARS-CoV-2 Serum
Other: Placebo

First Posted Date: 2021-04-06

Last Posted Date: 2021-04-08

Lead Sponsor: Butantan Institute

Target Recruit Count: 618

Registration Number: NCT04834089

Locations: 🇧🇷
Hospital do Rim, Sao Paulo, SP, Brazil
🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine

Phase 4

Completed

Conditions: Covid19

Interventions: Biological: Adsorbed COVID-19 (Inactivated) Vaccine

First Posted Date: 2021-02-10

Last Posted Date: 2024-02-15

Lead Sponsor: Butantan Institute

Target Recruit Count: 27711

Registration Number: NCT04747821

Locations: 🇧🇷
Hospital Estadual de Serrana, Serrana, SP, Brazil

Home Terms & Conditions Privacy Policy